Pulmatrix Historical Financial Ratios
| PULM Stock | USD 6.78 0.38 5.31% |
Pulmatrix is promptly reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 5.38, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 0.14 will help investors to properly organize and evaluate Pulmatrix financial condition quickly.
Pulmatrix |
About Pulmatrix Financial Ratios Analysis
PulmatrixFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Pulmatrix investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Pulmatrix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Pulmatrix history.
Pulmatrix Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Pulmatrix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pulmatrix sales, a figure that is much harder to manipulate than other Pulmatrix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Pulmatrix dividend as a percentage of Pulmatrix stock price. Pulmatrix dividend yield is a measure of Pulmatrix stock productivity, which can be interpreted as interest rate earned on an Pulmatrix investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Pulmatrix's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Pulmatrix current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.At this time, Pulmatrix's Capex To Revenue is very stable compared to the past year. As of the 11th of March 2025, Days Payables Outstanding is likely to grow to 49.45, while Book Value Per Share is likely to drop 5.38.
| 2024 | 2025 (projected) | Dividend Yield | 0.12 | 0.1 | Price To Sales Ratio | 1.07 | 1.02 |
Pulmatrix fundamentals Correlations
Click cells to compare fundamentals
Pulmatrix Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pulmatrix fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 2.71 | 4.59 | 2.2 | 0.93 | 1.07 | 1.02 | |
| Ptb Ratio | 1.48 | 0.5 | 0.43 | 0.38 | 0.34 | 0.36 | |
| Days Sales Outstanding | 2.43 | 4.73 | 78.04 | 46.41 | 53.37 | 96.42 | |
| Book Value Per Share | 16.09 | 17.52 | 9.02 | 4.93 | 5.67 | 5.38 | |
| Operating Cash Flow Per Share | (8.68) | (7.28) | (5.61) | (4.38) | (3.94) | (4.14) | |
| Stock Based Compensation To Revenue | 0.0917 | 0.22 | 0.18 | 0.13 | 0.15 | 0.14 | |
| Capex To Depreciation | 0.27 | 0.12 | 0.0557 | 0.46 | 0.53 | 0.47 | |
| Pb Ratio | 1.48 | 0.5 | 0.43 | 0.38 | 0.34 | 0.36 | |
| Ev To Sales | 0.34 | (5.38) | (3.52) | (0.5) | (0.57) | (0.54) | |
| Free Cash Flow Per Share | (8.88) | (7.34) | (5.64) | (4.56) | (4.11) | (4.31) | |
| Roic | (0.0263) | (0.39) | (0.5) | (0.48) | (0.56) | (0.53) | |
| Net Income Per Share | (19.83) | (8.31) | (5.43) | (3.87) | (3.48) | (3.65) | |
| Sales General And Administrative To Revenue | 0.55 | 1.23 | 1.12 | 0.89 | 1.03 | 0.98 | |
| Research And Ddevelopement To Revenue | 1.24 | 2.98 | 3.0 | 2.13 | 2.45 | 2.32 | |
| Capex To Revenue | 0.0222 | 0.0279 | 0.0142 | 0.0926 | 0.11 | 0.18 | |
| Cash Per Share | 22.02 | 19.88 | 10.33 | 5.25 | 6.04 | 5.74 | |
| Pocfratio | (2.74) | (1.2) | (0.69) | (0.42) | (0.38) | (0.4) | |
| Capex To Operating Cash Flow | (0.0225) | (0.0073) | (0.004443) | (0.0423) | (0.0381) | (0.0362) | |
| Pfcf Ratio | (2.68) | (1.19) | (0.69) | (0.41) | (0.37) | (0.39) | |
| Income Quality | 0.65 | 0.98 | 1.03 | 1.13 | 1.02 | 0.58 | |
| Roe | (1.23) | (0.47) | (0.6) | (0.78) | (0.71) | (0.74) | |
| Ev To Operating Cash Flow | (0.34) | 1.41 | 1.11 | 0.23 | 0.2 | 0.21 | |
| Pe Ratio | (0.48) | (0.71) | (1.2) | (1.05) | (0.43) | (0.45) | |
| Return On Tangible Assets | (0.82) | (0.38) | (0.46) | (0.42) | (0.37) | (0.39) | |
| Ev To Free Cash Flow | (0.34) | 1.4 | 1.1 | 0.22 | 0.2 | 0.21 | |
| Earnings Yield | (1.42) | (0.83) | (0.95) | (1.4) | (2.39) | (2.51) | |
| Net Debt To E B I T D A | 3.03 | 3.36 | 2.0 | 0.79 | 0.71 | 0.74 | |
| Current Ratio | 3.94 | 12.33 | 7.6 | 5.33 | 4.8 | 4.14 | |
| Tangible Book Value Per Share | 13.61 | 17.52 | 9.02 | 4.93 | 5.67 | 5.38 | |
| Receivables Turnover | 150.4 | 77.15 | 4.68 | 7.86 | 7.08 | 6.72 | |
| Shareholders Equity Per Share | 16.09 | 17.52 | 9.02 | 4.93 | 5.67 | 5.38 | |
| Debt To Equity | 0.0753 | 0.0482 | 0.0275 | 0.49 | 0.56 | 0.53 | |
| Capex Per Share | 0.0693 | 0.2 | 0.0532 | 0.0249 | 0.19 | 0.21 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.